Nuvilex Cites Study that Suggests Red Yeast Rice, an Active Ingredient in Cinnechol,...

Nuvilex Cites Study that Suggests Red Yeast Rice, an Active Ingredient in
Cinnechol, Can Help to Improve Cardiovascular Health

Study Published in Annals of Internal Medicine

CHERRY HILL, N.J., June 24 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC
Bulletin Board: NVLX), an emerging healthcare consumer products company,
announced today that red yeast rice, an ingredient contained in Cinnechol, one
of the Company's primary supplement products, has been recently proven to
decrease levels of low-density lipoprotein, or LDL cholesterol, in
dyslipidemic patients. LDL cholesterol is known more informally as "bad"
cholesterol. Red yeast rice, which has been used in Ayurvedic medicine and
China as a dietary supplement for centuries, contains a compound (monacolin K)
that is identical in chemical composition to lovastatin, a commonly prescribed
cholesterol-lowering drug.

A recent study titled "Red Yeast Rice for Dyslipidemia in Statin-Intolerant
Patients: A Randomized Trial," led by cardiologists Dr. David Becker and Dr.
Ram Gordon and published in the Annals of Internal Medicine, showed that a
diet and exercise regimen that included red yeast rice reduced LDL cholesterol
by an average of 27.3%, compared to 5.7% for the control group. Moreover, the
study showed that red yeast rice can decrease LDL cholesterol without
increasing pain levels.

"Many synthetic statins have been derived from red yeast rice and other
naturally occurring phytochemicals," stated Robert Bowker, co-inventor of
Cinnechol and President of Knock-Out Technologies, Ltd., a wholly owned
subsidiary of Nuvilex. "Red yeast rice, among others, is a bona fide naturally
occurring statin. Cinnechol--along with diet and exercise--can help
individuals maintain normal cholesterol levels and promote cardiovascular
health."

Cinnechol, which contains red yeast rice extract as well as a blend of other
ingredients known to improve cardiovascular function (including niacin and
guggul gum extract), may provide a natural alternative for those who have high
cholesterol and are intolerant of, or elect not to take, statin drugs.
Cinnechol can be purchased online by visiting www.cinnechol.com.

"Red yeast rice has now been more thoroughly researched and recognized as an
important tool for safely normalizing blood lipids, especially LDL
cholesterol," reported Cinnechol co-inventor Steven Kushner, Ph.D. "Cinnechol,
by combining Red Yeast Rice with several cardiovascular beneficial synergists,
also helps promote healthy total cholesterol levels, improved HDL (beneficial
cholesterol) levels, and better blood viscosity."

About Cinnechol

Cinnechol, an ingestible capsule made of all-natural ingredients, is
manufactured and sold by Cinnechol, Inc. (a wholly owned subsidiary of
Nuvilex, Inc.). Cinnechol is designed to help maintain normal cholesterol
levels and to support normal cardiovascular function. Cinnechol, along with a
healthy diet and exercise regimen, is intended to serve as a dietary
supplement to help individuals manage numerous cardiovascular and metabolic
disorders (including dyslipidemia, hypertension, hypoglycemia, and
hyperglycemia).

About Nuvilex, Inc.

Nuvilex, formerly eFoodSafety.com, is an emerging healthcare consumer products
company with a portfolio of aesthetics, dermatology, environmental and
nutraceutical products. The company's focus is on developing, licensing and
commercializing healthcare products that address the health needs of consumers
worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a
diversified skin products technology company serving the fast-growing body
art, aesthetic, cosmetic and skin therapy markets. More information is
available at: http://www.nuvilex.com or www.freedom2inc.com.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are
"forward-looking" statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities and Exchange Act of
1934. The forward-looking statements are made based on information available
as of the date hereof, and the Company assumes no obligation to update such
forward-looking statements. Forward-looking statements are sometimes
identified by words such as "intends", "anticipates", "believes", "expects",
and "hopes" and involve a number of risks and uncertainties that could cause
the Company's actual results to differ materially from projected results. All
parties are cautioned that such forward-looking statements involve risks and
uncertainties that could cause the Company's actual results to differ
materially from those in these forward-looking statements. Such risks and
uncertainties include but are not limited to demand for the Company's products
and services, the planned share exchange with Freedom2 Holdings, Inc., our
ability to secure additional financing, and other factors that may be more
fully described in reports to shareholders and periodic filings with the
Securities and Exchange Commission.

Investor Relations Contacts:

Blair Barnes
Senior Vice President and Chief Financial Officer
Nuvilex, Inc.
Ph: 856-433-6088
Email: bbarnes@nuvilex.com

Amy Glynn/Ashleigh Barreto
The Ruth Group
Ph: 646-536-7023/7028
Email: aglynn@theruthgroup.com
Email: abarreto@theruthgroup.com

Press Contact:

Pat Arcand
Arcand & Madison
Ph: 617-576-7777
Email: pat@am-pr.com

SOURCE Nuvilex, Inc.

Investor Relations: Blair Barnes, Senior Vice President and Chief Financial
Officer, Nuvilex, Inc., +1-856-433-6088, bbarnes@nuvilex.com; Amy Glynn,
+1-646-536-7023, aglynn@theruthgroup.com, or Ashleigh Barreto,
+1-646-536-7028, abarreto@theruthgroup.com, both of The Ruth Group; or Press
Contact: Pat Arcand, Arcand & Madison, +1-617-576-7777, pat@am-pr.com